Thrombosis Research (2005) 116, 545—550 THROMBOSIS RESEARCH oa ELSEVIER intl.elsevierhealth.com/journals/thre Author Index—Volumes 115-116 (2005) Abaci, A., 116:465 Bae, O.-N., 116:157 Blomback, M., 116:509 Abe, Y., 115:271; 116:307 Bai, X., 116:385 Boehlen, F., 115:131 Abeyama, K., 115:319 Baier, K., 115:135 Boisseau, M., 115:31 Abildgaard, U., 115:519 Balbay, Y., 115:25 Boivin, D., 115:143 Abrahamsson, T.|., 116:519 Balbi, M., 115:65 Boman, K., 116:249 Ageno, W., 116:301 Bang, N.U.; 115:73 Boneu, B., 116:293 Agnelli, G., 116:301 Banuelos, C., 115:101; 116:491 Bordet, J.C., 116:483 Agnese, A.M., 115:494 Barnes, T.A., 115:461 Borensztajn, K., 116:115 Ahmed, R.P.H., 115:535 Barrera-Ramirez, C., 115:101 Branner, S., 116:75 Aizawa, Y., 115:219 Barsotti, A., 115:65 Brennan, S.0., 115:293 Akar, N., 115:159, 393 Bartok, A., 115:469 Brenner, B., 116:109 Akin, M., 116:287 Baskin, E., 115:185 Broberg, A., 116:249 Aksu, K., 115:287 Bass, T.A., 115:101; 116:491 Broekman, M.J., 116:199 Al Yemeni, E., 116:377 Bayram, F., 116:465 Brunelli, C., 115:65 Alfonso, F., 115:101; 116:491 Baz-Hecht, M., 116:1 Brunet, C., 116:41 Almanric, K., 116:41 Bazinet, A., 116:41 Bruno, A., 115:73 Almshergi, Z.A., 116:451 Bazzan, M., 116:301 Budihna, M.V., 115:527 Altieri, P., 115:65 Beaulieu, E., 115:143 Alves-Filho, J.C.F., 115:537 Begaud, B., 115:31 Cabrera, J.L., 115:495 Amato, S., 116:443 Beight, D.W., 116:265 Cadroy, Y., 116:293 Ambrosio, G.B., 116:301 Beliveau, R., 115:143 Cagirgan, S., 115:287 Ammannati, F., 115:405 Bene, J., 116:479 Caldir, V., 115:25 Anand, S., 115:491 Berdeli, A., 116:287 Calevo, M.G., 116:443 Andresen, M.S., 115:519 Berggren, M., 116:249 Caliskan, M., 116:465 Angiolillo, D.J., 115:101; Berloco, P., 116:471 Calvo, J., 115:399 116:491 Bernardo, E., 115:101; 116:491 Cam, S.F., 116:287 Antovic, A., 116:509 Berntorp, E., 116:15 Carlsson, S.C., 115:9 Aoki, N., 116:455 Bersi, C., 116:207 Carmassi, F., 116:207 Aoyagi, K., 115:271 Bertero, G., 115:65 Caron, S., 116:41 Arnesen, H., 115:163, 257; Bertoldi, A., 116:301 Carroll, R.C., 116:51 116:313 Bertsch, T., 116:171 Cavallari, U., 116:491 Astermark, J., 116:15 Bhattacharya, M., 115:534 Celik, H.A., 115:287 Atalay, F., 115:159 Biswas, A., 115:535 Cengiz, N., 115:185 Aurigemma, C., 116:25 Bjorkman, J.-A.E., 116:519 Cerbone, A.M., 115:439 Ayaz, S., 115:25 Bjorn, S.E., 116:75 Cerne, M., 115:526 Aydin, H.H., 115:287 Blais, N., 116:41 Cetin, M., 116:465 Aznar, J., 115:263, 399; 116:447 Blann, A.D., 115:205; 116:181, Cetin, S., 116:465 377 Chafa, O., 116:115 Bach, J., 116:33 Blessing, F.J., 115:39 Chandler, W.L., 115:327 Badar, J., 116:55 Bliden, K.P., 115:89 Chang, G.-T., 116:421 0049-3848/S - see front matter « 2005 Elsevier Ltd. All rights reserved. doi:10.1016/S0049-3848(05)00386-5 546 Author Index Chang, T.-S., 115:309 Doganavsargil, E., 115:287 Gerrits, W.B.J., 115:381 Chen, C., 115:417 Dogne, J.-M., 116:431 Ghigliotti, G., 115:65 Chen, C.-Y., 115:153 Dole, W.P., 115:341 Ghuysen, A., 116:431 Chesebro, J.H., 116:525 Donmez, A., 115:287 Giannarelli, C., 116:207 Chiang, T.M., 115:503 D’Orio, V., 116:431 Giddings, J.C., 116:393 Chin, B.S.P., 116:181 Dorn-Beineke, A., 116:171 Gifford-Moore, D.S., 116:265 Choi, E.-Y., 116:421 Drevensek, G., 115:526 Gilmore, W.S., 115:109 Chong, A.Y., 116:181 Drion, P., 116:431 Gingras, D., 115:143 Christensen, J.H., 115:257 Drosopoulos, J.H.F., 116:199 Ginsberg, J., 115:1 Christensen, K., 115:245 Glazier, G., 115:143 Chung, |., 116:275 Ekman, G.J., 116:509 Goldenberg, N.A., 116:345 Chung, J.-H., 115:309; 116:157 Elder, R.F., 116:51 Golding, B., 116:335 Chung, K.-H., 116:421 Elgue, G., 115:245 Gorelick, P.B., 115:73 Chung, K.-Y., 116:157 Elhan, A.H., 115:393 Grabowski, E.F., 116:409 Chung, S.-M., 116:157 Eliasson, A., 115:9 Granlund, A., 116:249 Cirillo, F., 115:439 Elm, T., 116:75 Grill, D.E., 116:525 Cohen, S.N., 115:73 El-Omar, M.M., 116:199 Guazzaloca, G., 116:301 Colucci, M., 116:471 Emanuelsson, H., 115:245 Guglielmone, H.A., 115:495 Contreras, M.T., 115:399 Emi, Y., 116:215 Guiral, V., 115:263 Cooley, B.C., 115:153 Endo, S., 116:357 Gumulec, J., 115:427 Coppola, A., 115:439 Ercan, E., 116:287 Guray, U., 115:25 Corella, D., 115:399 Eriksson, U.G., 115:9 Guray, Y., 115:25 Cosman, F., 116:1 Ernam, D., 115:159 Gurbel, P.A., 115:89 Costa, M.A., 115:101; 116:491 Escaned, J., 115:101, 116:491 Covic, L., 116:55 Espana, F., 115:399 Haddad, N., 116:109 Crea, F., 116:25 Hallqvist, J., 116:223 Crowther, M.A., 115:3 Fattal-Valevski, A., 116:133 Hamasaki, N., 115:351 Cruz, J.D., 116:1 Fernandez-Ortiz, A., 115:101; Hanson, J., 116:431 Cullinane, A.M., 116:499 116:491 Hanson, S.R., 115:79 Cushman, M., 116:1 Ferrando, F., 116:447 Harel, S., 116:133 Cvirn, G., 115:135 Fioriti, R., 116:207 Harish Kumar, M., 116:255 Fischer, A.-M., 116:115 Hashiguchi, T., 115:319 Dally, N., 116:109 Fischer, J.E., 115:175 Hashimoto, N., 116:215 Dampier, K., 115:461 Fischler, B., 116:185 Hassinger, N.L., 116:525 Dargaud, Y., 116:483 Fisher, M., 115:435 Hassner, A., 116:133 Datta, Y., 115:153 For the Warfarin Optimal Hathaway, W.E., 116:345 De Boer, R.A., 116:279 Duration Italian Trial (WODIT) Havasi, V., 116:479 De Caterina, R., 115:163, 257 Investigators, 116:301 Hayakawa, M., 116:91 De Faire, U., 116:223 Forslund, M., 116:241 Hayakawa, Y., 116:357 De Giorgi, A., 116:207 Francis, C., 115:1 Hayashi, N., 116:357 De Moerloose, P., 115:131 Frederick, M., 115:327 He, S., 116:509 De Negri, F., 116:207 Friedman, K.D., 115:153 Held, P., 115:9 De Simone, C., 115:439 Fruzzetti, F., 116:207 Hellstern, P., 116:33 Dechavanne, M., 116:483 Fujikawa, K., 115:441 Hemker, H.C., 115:255 Deda, G., 115:393 Funahashi, T., 115:483 Hennessey, M.D., 116:51 DeLa Cadena, R.A., 116:533 Fuse, |., 115:219 Heptinstail, S., 115:301 Dell’Omo, G., 116:207 Hernandez, R., 115:101; Dempfle, C.-E., 116:171 Gabriel, F., 115:263 116:491 Deng, G., 115:341 Gallistl, S., 115:135 Hillbom, M., 115:367 Deng, Y., 116:451 Gando, S., 116:91 Hillege, H.L., 116:279 Denis Alexander, H., 115:109 Garcia-Herola, A., 116:321 Hiller, E., 116:233 Deol, P.S., 115:461 Garibaldi, S., 115:65 Hirashima, Y., 116:357 Depont, F., 115:31 Gasztonyi, B., 116:479 Hirokawa, T., 115:475 Devoto, E., 115:65 Geisen, C., 115:534 Hjemdahl, P., 116:509 Di Leo, A., 116:471 Gende, 0.A., 116:67 Hjerkinn, E.M., 116:313 Do, Y.H., 116:265 George, P.M., 115:293 Hoffman, R., 116:109 Author Index Hokamaki, J., 115:483 Kamikura, Y., 115:53; 116:307 Kurihara, M., 115:351 Honda, O., 115:483 Kang, H.-M., 115:327 Kurimoto, M., 116:357 Horne Ill, M.K., 116:499 Kannan, M., 115:534 Kushak, R.|., 116:409 Hoshino, H., 116:91 Karahan, Z.C., 115:393 Kuwayama, N., 116:357 Howley, H.E.A., 116:101 Karalis, |., 116:377 Hu, H., 116:241 Kario, K., 115:475 Labios, M., 115:263 Huang, H.-Y., 116:145 Karlson, B.W., 115:9 Lalonde, L., 116:41 Huber, K., 115:469 Katayama, K., 116:215 Lamassa, M., 115:405 Hudig, F., 115:381 Katayama, M., 116:215 Lambermont, B., 116:431 Hursting, M.J., 116:121 Kathriner, S., 116:165 Lambert, J., 116:409 Huwer, H., 116:33 Kato, H., 116:91 Lane, J.R., 115:45 Katori, N., 115:79 Lanza, G.A., 116:25 Ichikawa, S., 115:359 Kavlie, A., 116:313 Larosa, C., 116:25 lida, H., 115:351 Kawano, H., 115:483 Larsson, A., 115:245 ljiri, Y., 115:115 Kazahaya, Y., 115:53 Larsson, R., 115:245 ljiru, Y., 116:393 Kelly, A.B., 115:79 Le Bonniec, B., 116:115 lIkarugi, H., 116:127, 403 Kelton, J.G., 116:121 Leander, K., 116:223 Ikeda, T., 116:215 Kenet, G., 116:133 Lechner, K., 115:59 Ikeda, Y., 115:191 Kerényi, A., 116:139 Lee, B.-H., 115:309 Imanaka, T., 116:215 Keser, G., 115:287 Lee, G.-Y., 115:309 Imberti, D., 116:365 Khil, L.-Y., 115:309 Lee, K.-S., 115:309 Inal, V., 115:287 Kim, C.-H., 116:421 Lee, M.-Y., 116:157 Infusino, F., 116:25 Kim, D., 115:309 Lee, S.-J., 116:157 Ingelfinger, J.R., 116:409 Kim, J.A., 115:435 Lehr, S., 115:59 Inman, J., 116:335 Kim, J.-H., 116:421 Leitner, Y., 116:133 Inoue, A., 116:127, 403 Kim, Y.-C., 115:309 Leschnik, B., 115:135 Inoue, S., 115:351 Kimmelstiel, C., 116:55 Lethagen, S., 116:15 Ishii, H., 116:127, 403 Kinoshita, S., 115:351 Lewis, B.E., 116:121 Ishii, K., 115:191 Kirazli, S., 115:185 Li, N., 116:241 Ishikura, K., 115:53; 116:307 Kirszberg, C., 115:123 Liang, A., 115:341 Isik Agras, P., 115:185 Kitagawa, A., 115:483 Liestol, S., 115:509 Islam, N., 116:199 Kitajima, |., 116:215 Lignot, S., 115:31 lsordia-Salas, |., 116:533 Kitamari, K., 116:127 Lin, P., 115:417 Iwamoto, H., 115:319 Klement, P., 115:427 Lindman, A.S., 116:313 lwasaka, T., 115:277 Kliber, A., 115:491 Lindsay, R., 116:1 Iwata, M., 115:211 Klimkowski, V.J., 116:265 Lip, G.Y.H., 115:171, 205; Knobl, P., 115:59 116:181, 275, 321, 377 Jacobson, A., 115:45 Kobayashi, T., 116:307 Liu, C.-Z., 116:145 Jacobson, L., 116:345 Koestenberger, M., 115:135 Liu, Y., 115:319 Jacques, S., 116:55 Kojima, S., 115:483 Lorin, J.D., 116:199 Jacquet, A., 115:31 Kolb, H.J., 116:233 Lu, D., 116:265 Jaeger, B., 115:39 Kolh, P., 116:431 Lumsden, A.B., 115:417 Jager, U., 115:59 Komlosi, K., 116:479 Jansen, R.W., 115:381 Kono, M., 115:271 Macaya, C., 115:101; 116:491 Jansson, J.-H., 116:249 Kopp, C.W., 115:469 Maccallini, A., 116:25 Jetzl, A., 115:469 Korkmaz, S., 115:25 MacFadyen, R.J., 115:205 Ji, S., 116:385 Koschinsky, M.L., 115:491 Maghzal, G.J., 115:293 Jiang, M., 116:385 Kotze, H., 115:79 Magis, D., 116:431 Jimenez-Quevedo, P., 116:491 Krishna Biswas, K., 115:319 Makris, M., 115:451 Johnston, M., 115:427 Kristensen, S.D., 115:163, 257 Matyszko, J., 115:19 Jones, S.W., 115:341 Kroner, C., 116:327 Matyszko, J.S., 115:19 Juvela, S., 115:367 Kudielka, B.M., 115:175 Manco-Johnson, M.J., 116:345 Kuliopulos, A., 116:55 Manns, J.M., 116:533 Kalnoski, M.H., 115:327 Kumakura, H., 115:359 Marcus, A.J., 116:199 Kalweit, G., 116:33 Kupferminc, M.J., 116:133 Marin, F., 116:321 Kameue, T., 116:91 Kurabayashi, M., 115:359 Mariotti, F., 115:405 548 Author Index Marroni, A.S., 115:375 Muntean, W., 115:135 Palmieri, N.M., 115:439 Marsh, J.J., 115:45 Muradin, A.A., 115:381 Papp, E., 116:479 Martineau, J., 116:41 Murata, M., 115:191 Parekh, H., 116:533 Martinez, E., 115:263 Muszbek, L., 116:139 Parretti, E., 115:405 Martinez, M., 115:263 Mysliwiec, M., 115:19 Pasi, K.J., 115:461 Maruyama, |., 115:319 Patteson, S.K., 116:51 Maruyama, M., 116:255 Nadar, S.K., 116:377 Pavord, S.R., 115:461 Maruyoshi, H., 115:483 Nadasi, E., 116:479 Pchelina, S.N., 115:199 Marzec, U., 115:79 Naemura, A., 115:115 Pedersen, J.|., 116:313 Maser, E., 116:101 Nagassaki, S., 115:375 Pedrinelli, R., 116:207 Masereel, B., 116:431 Nakamura, T., 115:211 Peng, L., 115:427 Matsuda, M., 115:53 Nakano, T., 115:53, 211, Penovici, M., 116:233 Matsuda, N., 116:91 116:215, 307 Pentimone, A., 116:471 Matsumoto, T., 115:53 Nan, B., 115:417 Perneby, C., 116:509 Matsuo, T., 115:475 Naritomi, H., 115:455 Persson, E., 116:75 Matsuzawa, Y., 115:483 Negrier, C., 116:483 Perutelli, P., 116:443 Matthai Jr., W.H., 116:121 Nemeth, A., 116:185 Pétein, M., 116:431 Mattsson, C., 115:9 Nerme, V.K., 116:519 Peternel, L., 115:527 Mattsson, C.J., 116:519 Nestoridi, E., 116:409 Petersen, L.C., 116:75 May, J.A., 115:301 Nieves, D.R., 115:1 Petrini, P., 116:185 Mazet, M., 116:483 Nieves, J.W., 116:1 Pettersson, M., 116:185 McBane Il, R.D., 116:525 Nilsson, G., 116:15 Pignatti, P.F., 116:491 McConnell, J.P., 115:73 Nilsson, T.K., 116:249 Pihusch, M., 116:233 McGlynn, H., 115:109 Nishiguchi, M., 115:271 Pihusch, R., 116:233 Mclachlan, C., 116:451 Nishikawa, M., 115:277; Pihusch, V., 116:233 Melegh, B., 116:479 116:307 Pirotte, B., 116:431 Melegh, G., 116:479 Nishioka, J., 116:307 Prandoni, P., 116:301 Mello, G., 115:405 Niwano, H., 115:219 Preckel, D., 115:175 Mennonna, P., 115:405 Nobori, T., 115:53; 116:307 Prisco, D., 116:365 Merchlinsky, M., 116:335 Nomura, S., 115:277; 116:215 Provencal, M., 115:143 Merryman, P.K., 116:499 Norby, P.L., 116:75 Pulte, E.D., 116:199 Mesterman, R., 116:133 Nordenhem, A., 116:223 Pyhtinen, J., 115:367 Metzger, |.F., 115:375 Nunez Montoya, S.C., 115:494 Miall, F.M., 115:461 Radha, K.S., 116:255 Middeldorp, J.M., 115:387 Oda, E., 115:115, 116:393 Rak, J., 115:427 Minar, E., 115:469 Ogawa, H., 115:483 Ramirez, C., 115:101; 116:491 Minematsu, K., 115:455 Oguchi, S., 115:191 Rasmussen, L.H., 115:163, Mira, Y., 116:447 Oh, J.-Y., 116:421 257 Mischke, R., 115:229 Ohmori, T., 115:409 Ratel, D., 115:143 Mischler, K., 115:175 Okada, Y., 116:403 Rathnachalam, R., 116:265 Miyamoto, S., 115:483 Okten, F., 115:159 Reber, G., 115:131 Moia, M., 116:301 Oldenburg, J., 115:534 Rechner, A.R., 116:327 Molinari, A.C., 116:443 Olson, K.E., 116:199 Reghis, A., 116:115 Monteiro, R.Q., 115:123 Olwill, S.A., 115:109 Ricart, J.M., 115:399 Moon, C.-H., 115:309 Omay, S.B., 115:287 Richardson, D., 115:73 Moon, C.-K., 115:309 Omoto, S., 115:277 Rimon, E., 116:133 Moore, N., 115:31 Omura, S., 116:255 Riutta, A., 115:367 Moreno, R., 115:101; 116:491 On behalf of HIT Research Riviello, C., 115:405 Moreno-Aspitia, A., 116:87 Group of Japan, 115:475 Roa, D.C., 116:199 Moriki, T., 115:191 Ono, M., 115:351 Rodger, M.A., 116:101 Morris, T.A., 115:45 Oppenheimer, C.A., 115:461 Roldan, V., 116:321 Morser, J., 115:341 Osada, M., 115:409 Rolin, S., 116:431 Mossop, P.J., 116:451 Owers, R.L., 116:51 Rosendaal, F.R., 115:387 Mozsik, G., 116:479 Ozaki, Y., 115:409 Ross, C.M., 116:273 Mruk, J.S., 116:525 Ozawa, T., 116:215 Rossettin, P., 115:65 Muenchen, R.A., 116:51 Ozbek, N., 115:185 Rossiello, M.R., 116:471 Author Index Rowe, J.M., 116:109 Sirotkina, O.V., 115:199 Tsuda, Y., 116:403 Ruan, C., 116:385 Snider, C.C., 116:51 Tufano, A., 115:439 Rumjanek, V.M., 115:123 Snider, R.M., 115:341 Turcotte, |., 116:41 Russo, F., 116:471 Soejima, H., 115:483 Rutten, W.P.F., 115:239 Soltész, P.,, 116:139 Uchimura, T., 115:319 Serensen, B.B., 116:75 Uchiyama, S., 115:211 Saatci, U., 115:185 Souza-Costa, D.C., 115:375 Umar, A., 115:31 Sabate, M., 115:101; 116:491 Spallarossa, P., 115:65 Unal, A., 116:465 Sagcan, A., 116:287 Sperr, W.R., 115:59 Uzuelli, J.A., 115:375 Sainz, |., 116:533 Stalc, A., 115:526 Sakamaki, T., 115:359 Stefenelli, T., 115:469 Valent, P., 115:59 Sakamoto, H., 115:359 Stegnar, M., 115:526 Van den Besselaar, A.M.H.P., Sakamoto, T., 115:483 Steiner, S., 115:469 115:239 Sakariassen, K., 116:293 Sten-Linder, M., 116:223 Van der Meer, F.J.M., 115:387 Sakata, T., 115:455 Stennicke, H.R., 116:75 Van Strijen, M.J.L., 115:381 Saloheimo, P., 115:367 Stiell, |., 116:101 Van Veldhuisen, D.J., 116:279 Samara, W.M., 115:89 Storey, R.F., 115:301 Vardy, M.D., 116:1 Sandor, J., 116:479 Sugiki, M., 116:255 Varricchione, N., 115:439 Sandset, P.R., 115:1 Sugiyama, S., 115:483 Vavilova, T.V., 115:199 Sano, T., 115:115; 116:393 Sumino, H., 115:359 Vaya, A., 115:399, 116:447 Santamaria, M.G., 116:301 Szegedi, G., 116:139 Veierod, M.B., 116:313 Sarich, T.C., 115:9 Szolnoki, Z., 116:479 Veres, K., 116:139 Sarig, G., 116:109 Verheugt, F.W.A., 116:279 Sase, T., 116:307 Takahashi, H., 115:219 Vermeer, H.J., 115:381 Sato, A., 116:127 Takamura, N., 115:271 Vernersson, E., 116:15 Sato, N., 115:219 Takayama, Y., 115:359 Villa, P., 116:447 Sawada, Y., 115:359 Takeshita, E., 115:191 Viasin, M., 115:427 Sawai, T., 115:53 Talian, G., 116:479 Von Kanel, R., 115:175 Saxena, R., 115:535 Taliani, M.R., 116:301 Scherjon, S.A., 115:387 Tanabe, N., 115:219 Wada, H., 115:53, 116:307 Schmidt, E.B., 115:163, 257 Tanaka, K.A., 115:79 Wada, Y., 115:351 Schoon, H.-A., 115:229 Tanaka, Y., 116:215 Wahlander, K., 115:9 Schulman, S., 116:185 Tantry, U.S., 115:89 Wajcman, H., 116:115 Schwartz, E.|I., 115:199 Tanus-Santos, J.E., 115:375 Wakiyama, M., 115:351 Sedlis, S.P., 116:199 Tapon-Bretaudieére, J., 116:115 Wallen, H.N., 116:509 Segers, P., 116:431 Taraskina, A.E., 115:199 Walli, A.K., 115:39 Segur, M.C., 115:31 Tayebjee, M.H., 115:205 Wang, W., 116:335 Seidel, D., 115:39 Tchana-Sato, V., 116:431 Wang, X., 115:95 Seidinger, D., 115:469 Tengiz, |., 116:287 Wang, Y., 115:39, 319; 116:385 Seifried, E., 115:534 Thalamas, C., 116:293 Warshawsky, A.M., 116:265 Seki, Y., 115:219 Thogersen, A.M., 116:249 Waser, G., 116:165 Sekuri, C., 116:287 Thrall, G., 115:171 Watanabe, K., 115:191, 351 Selig, M.K., 116:409 Tietjen, G.E., 115:73 Watson, C.C., 115:461 Seljeflot, |., 116:313 Tjeerdsma, G., 116:279 Waxman, S., 116:55 Semeraro, N., 116:471 Toba, K., 115:219 Weintraub, A., 116:55 Sestito, A., 116:25 Todoli, J., 115:399 Weitz, J.l., 115:427 Sgueglia, G.A., 116:25 Tomaru, T., 115:475 Wells, P.S., 116:101 Shah, A.K., 116:87 Tomasi, C., 116:301 Weltermann, A., 115:59 Sheth, S.B., 115:9 Tombuloglu, M., 115:287 Wijermans, P.W., 115:381 Shih, M.-H., 116:145 Tondi, F., 115:405 Wiman, B., 116:223 Shiku, H., 115:53, 116:307 Toth, K., 116:479 Winning, J., 116:33 Shindo, H., 115:271 Trabetti, E., 116:491 Wisloff, F., 115:3 Shouzu, A., 115:277 Tran, K., 115:341 Wisloff, F., 115:509 Shwarzman, A.L., 115:199 Tran, N.D., 115:435 Wisser, H., 116:171 Silingardi, M., 116:301 Trzeciak, M.C., 116:483 Witsenburg, C.P.J., 115:387 Sipahi, T., 115:393 Tsai, P.-J., 116:145 Witteveen, E., 115:239 Author Index 550 Ue Wittmann, |., 116:479 Yamamoto, H., 116:357 Yoshida, E., 116:255 Wohlsein, P., 115:229 Yamamoto, J., 115:115, Yoshimura, M., 115:483 Wu, F., 115:341 116:127, 393, 403 Ypma, P., 115:381 Wu, Q., 115:341 Yamashita, T., 115:115; Wuillemin, W.A., 116:165 116:127, 393, 393, 403 Zgraggen, L., 115:175 Yamazaki, M., 115:211 Zhao, Z., 115:341 Xiong, Y., 115:211 Yao, Q., 115:417 Zhou, W., 115:435 Xu, L., 115:95 Yasaka, M., 115:455 Zhu, H., 116:385 Yatomi, Y., 115:409 Zhu, J., 115:503 Yamada, N., 115:53; 116:307 Ye, B., 115:341 Ziegler, S., 115:59 Yamaji, K., 115:319 Yilmaz, M.B., 115:25 Zion, M., 116:1 Yamakoshi, J., 115:115 Yilmaz, Y., 116:465 Thrombosis Research (2005) 116, 551 THROMBOSIS eGre)e oa a RESEARCH - ELSEVIER intl.elsevierhealth.com/journals/thre Keyword Index—Volumes 115-116 (2005) 20210A, 115:351 Antigen, 116:307 Bleeding, 116:109 Acetylsalicylic acid, 116:139, Antioxidant, 115:417 Blood coagulation, 115:175, 191 293 Antiphospholipid antibodies, Blood coagulation disorders, Acquired factor V inhibitor, 115:3 116:15 116:87 Antiphospholipid syndrome, Blood coagulation tests, 116:9 Activated clotting time, 115:9 115:405 Blood collection tube, 115:239 Activated FXII, 115:65 Antiplatelet, 116:293 Brazilin derivative, 115:309 Activated partial thromboplas- Antiplatelet activity, 115:495 Bypass graft occlusion, 115:39 tin time, 115:9 Antiplatelet agent, 115:309 Activated protein C, 115:319 Antithrombin, 115:519, C57BL/6 mice, 115:115 Acute coronary syndrome, 116:15, 171 Ca** mobilization, 115:409 115:475 Antithrombin deficiency, Calcium, 116:241 Acute coronary syndromes, 116:215 Cangrelor, 115:301 115:65 Antithrombotic, 115:95, CAPD, 115:19 Acute leukemia, 115:59 116:293 Carboxypeptidase, 116:499 Acute myeloid leukaemia, Antithrombotics, 115:341 Carboxypeptidase U, 116:519 115:109 Anti-Xa activity, 116:41 Cardiac thrombus, 115:159 Acute promyelocytic leukemia, ApoE LDLR double knockout Cardiopulmonary bypass, 116:109 mouse, 116:393 115:327 Adenovirus, 116:357 Aprotinin, 115:327 Cardiopulmonary bypass Adhesion molecules, 115:19; Argatroban, 116:121 surgery, 116:33 116:91 Armagnac, 115:31 Cardiovascular diseases, Adiponectin, 115:483 Arterial thrombosis, 115:95 116:199 ADP, 115:31, 116:55 ASA treatment, 116:509 CD146, 115:19 Adult plasma, 115:135 Aspirin, 115:211, 367; 116:465, Cell cycle, 115:219 Advanced glycation end 483 Cell detachment, 116:409 products, 115:319 Aspirin resistance, 115:25 Cerebral cavernoma, 115:405 Age, 115:205 Atherosclerosis, 115:73, 482; Cerebral hemorrhage, 115:367 Age-dependent, 116:127 116:393 Cerebral palsy, 116:133 Aggregation, 115:89 Atorvastatin, 115:263 CHADS, 116:321 Animal model, 115:95; 116:335 ATRA, 116:109 Chemokine, 115:277 Annexin Il, 115:109 Atrial fibrillation, 116:321 Child, 116:185 Anti coagulant therapy, 116:279 Autologous growth factor, Children, 115:185 Anti platelet therapy, 116:279 116:87 Chloride -b icarbonate Anticoagulant, 116:41 Automation, 116:171 exchanger, 116:67 Anticoagulant protein, 116:421 Cholesterol, 115:375 Anticoagulants, 115:245 B16F10 melanoma, 115:123 Cilostazol, 115:211 Anticoagulation, 115:45, Behcet’s disease, 115:159, 287, Clopidogrel, 115:89, 101; 116:121 399 116:55, 293, 491 $0049-3848/S - see front matter © 2005 Elsevier Ltd. All rights reserved. doi: 10.1016/S0049-3848(05)00387-7 552 Keyword Index Coagulation, 115:159, 359, Endothelial cell damage, Flaveria bidentis, 115:495 519; 116:171, 345, 421 115:219 Flow cytometry, 115:263, Coagulation activation and Endothelial cell, 115:417 116:241 fibrinolysis markers, 116:33 Endothelial cells, 116:233, 409 Framingham, 116:321 Coagulation factor V, 116:533 Endothelial damage, 116:181 Function, 116:465 Coagulation factors, 116:75 Endothelial dysfunction, FV Leiden mutation, 115:519 Coagulation FVII, 116:313 116:181 Collagen, 115:503 Endothelial function, 116:207 Gastrointestinal haemorrhage, Computer modeling, 115:327 Endothelial nitric oxide 116:185 Contact activation, 116:33 synthase (eNOS), 115:375 Gender, 115:205 Coronary artery disease (CAD), Endothelial nitric oxide Gene analysis, 115:351 115:469, 483 synthase, 116:287 Gene mutation, 116:115 Copenhagen rat, 115:153 Endothelial protein C receptor, Gene polymorphism, 116:287 Coronary artery thrombosis, 115:417 Gene therapy, 116:335 116:519 Endothelium, 115:19, 435; Global assay, 116:345 Coronary disease, 116:525 116:199 Global fibrinolytic capacity, Coronary heart disease, Eptifibatide, 115:79 115:185 115:163 E-selectin, 116:181 Global haemostatic tests, C-reactive protein (CRP), Estrogen, 115:359; 116:1 116:15 115:482 Ethnicity, 115:205 Glycoprotein Ilb/Illa, 115:263, Critical stenosis, 115:427 Exercise, 115:205 503; 116:145 CRM-negative, 115:191 Experimental model, 115:527 Glycoproteins, 115:245 CTL epitope, 116:335 Expression, 116:75 GPVI, 115:409 Curcumin, 115:417 Expression study, 115:191 Graft occlusion, 115:25 Cyclo-oxygenase 1 deficiency, Extracellular matrix, 115:205 116:483 H. pylori infection, 116:471 Cyclosporin A, 115:219 Haemangiosarcoma, 115:229 CYP2C9 polymorphism, 115:199 Factor FVIl deficiency, 116:115 Haemostasis, 115:229; 116:185 Factor ll, 116:133 Healthy volunteers, 115:31 3D microscopy, 116:509 factor V Leiden, 115:351 Heart failure, 116:181, 279 D-dimer, 115:53, 271 Factor V leiden, 116:133 HELLP syndrome, 115:387 D-dimer testing, 116:165 Factor Vill, 115:387, 116:335 Hematocrit, 115:175 D-Dimer PLUS, 115:381 Factor Xa, 115:123 Hemodynamics, 116:431 Deep vein thrombosis, 115:351, Factor X!, 115:441 Hemophilia, 115:441 116:215, 301 Factor Xil, 115:191 Hemophilia A, 116:335 Deep venous thrombosis, Fibrates, 115:293 Hemorheology, 115:399 115:381, 116:165 Fibrin degradation products, Hemorrhagic complication, Deficiency, 115:191 115:229 115:455 Diabetes, 116:465 Fibrin degradation products by Hemostasis, 115:95, 367; 116:1 Diagnostic strategy, 116:165 granulocyte elastase, 115:53 Heparin, 115:45, 153, 301, 475 Dialysis, 115:185 Fibrin degradation, 115:143 Heparin cofactor Il, 116:357 Diet, 116:313 Fibrin fibrinogen degradation Heparin neutralization, Dipyridamole, 115:435 products, 115:381 115:509 Dipyridamole, 116:293 Fibrin gel permeability, 116:509 Heparin-induced thrombocyto- Direct thrombin inhibitor, Fibrinogen, 115:39, 293; penia, 115:475; 116:121 116:121 116:145, 171, 241 Heparin-mediated extracorpor- Disseminated intravascular Fibrinogen consumption, eal low-density lipoprotein coagulation (DIC), 116:91 115:427 precipitation, 115:39 Disseminated intravascular Fibrinogen degradation, Hepatic sequestration, 115:79 coagulation, 115:536 115:143 High sensitive C-reactive pro- Diurnal variation, 115:205 Fibrinolusis, 115:359 tein, 116:249 Dog, 115:229 Fibrinolysis, 115:109, 327, 341; High-density lipoprotein choles- DVT, 115:53; 116:307 116:207, 265, 345 terol (HDL-C), 115:483 Fibrinolytic enzyme, 115:143 HL-60 cell line, 116:533 Ecarin clotting time, 115:9 Fibroblasts, 116:357 Human neutrophil elastase, Endocarditis, 116:145 Fish consumption, 115:163 116:533 Keyword Index 553 Human placenta protein, Medical patients, 116:365 Peripheral arterial disease, 116:421 Melagatran, 115:135 115:39 Human plasma, 116:157 Mental stress test, 116:25 PFA-100, 116:139 Human umbilical vein endothe- Metalloproteases, 115:143 PFA-100 testing, 116:483 lial cells, 115:219 Microparticles, 116:409 Phage display, 116:385 Hypercoagulability, 115:527 Mitomycin C, 115:219 Pharmacogenetics, 115:199 Hyperlipidemia, 115:263 Monitoring, 115:131 Pharmacokinetics, 115:45 Hypertension, 115:277, 359 Monoclonal antibodies, 115:245 Phosphatidylserine, 115:263 Monocytes, 116:471 Phospholipase A>, 115:309 IL-6, 115:393 Mortality, 116:15 Physical examination, 116:101 Impaired renal function, 116:41 Mouse, 115:95 Plasma kallikrein inhibitor, Infarction, 115:73 mRNA, 116:307 116:403 Inflammation, 115:417; 116:533 MRNA binding protein, 116:255 Plasma thrombosis, 115:73 In-frame deletion, 116:215 MRNA stability, 116:255 Plasma volume, 115:175 Inherited bleeding disorder, MTHFR, 116:133 Plasminogen activator inhibitor- 116:115 Multiple organ dysfunction syn- 1, 116:233 Inhibitor, 115:503 drome (MODS), 116:91 Plasminogen activator inhibitor- Inhibitors, 116:525 Murine factor Vil, 116:75 2, 116:471 INR, 115:239 Mutation, 115:191 Plasminogen, 115:109; 116:499 INR (international normalized Myocardial infarction, 116:139, Platelet, 115:89, 409, 503; ratio), 115:131 223, 431 116:127, 145, 385, 465, 483 Insulin resistance, 116:207 Myocardial ischemia, 116:33 Platelet activation, 115:211, Intensive care, 116:15 263; 116:377 Interleukin-6, 116:357 n—3, 116:393 Platelet adhesion, 116:377 Interobserver reliability, n—6, 116:393 Platelet aggregation, 115:31, 116:101 Nephrotic syndrome, 115:19 309, 495, 503; 116:241 Intima-media thickness (IMT), Neutrophil, 116:91 Platelet aggregation inhibitors, 115:482 Nifedipine, 115:277 115:301 Intracellular degradation, Nitrate, 115:375 Platelet function, 115:115; 116:215 Nitric oxide, 115:375; 116:403 116:491 Intracellular pH, 116:67 Nitrite, 115:375 Platelet membranes neutraliza- Intrauterine growth restriction, Normalized screening/ confirm tion, 116:421 115:387 ratio, 115:509 Platelet reactivity, 115:115; lron deprivation, 116:255 Nucleotide substitution, 116:25 Iron overload, 116:157 116:215 Platelets, 115:101, 245, 301, i-STAT System Portable Clinical 367, 536; 116:55, 67, 139, Analyser, 115:131 199, 233, 241, 403, 499, 525 Obesity, 116:41 Octreotide, 116:185 Platelets Thrombin, 115:441 Laser-induced thrombosis, Oral anticoagulants, 115:131, Pneumatic tourniquet (tourni- 115:115 199 quet), 115:271 LDL oxidation, 116:157 Oral direct thrombin inhibitor, Polycystic ovary syndrome, Leukocyte, 116:307 115:135 116:207 Lewis rat, 115:153 Oral direct thrombin inhibitors, Polymerisation, 115:293 Lipid peroxidation, 115:319 115:9 Polymorphism, 116:491 Lipoprotein (a), 115:39 Polymorphisms, 115:375; Liver diseases, 116:185 Low molecular weight heparin, P2 receptor, 115:301 116:313 115:45, 509; 116:41 PAI-1, 115:341; 116:127, 223, Polyphenols, 115:31 Lupus anticoagulant assays, 255 Polyunsaturated fatty acid, 115:509 PAI-1 inhibitor, 115:341 116:393 Lymphocytes, 116:199 Partial thromboplastin time, Polyunsaturated fatty acids, Lysine, 116:499 116:171 115:163 Percutaneous ccronary Post-transcriptional regulation, Magnesium, 115:239 intervention (PCI), 115:469 116:255 Matrix metalloproteinases, Percutaneous coronary Potentiation of platelet 115:205 intervention, 115:475 collagen activation, 116:51 24 Keyword Index PP27, 116:421 Recombinant factor Vila TAFla, 116:519 Prednisolone, 115:219 (rFVila), 116:185 Tamoxifen, 116:1 Pre-eclampsia, 115:387 Remnant-like particles, 115:211 TF, 116:307 Preeclampsia, 116:51, 377 Resonance thrombography, Thiols, 116:157 Pregnancy, 115:293, 405, 461 115:229 Thrombelastography, 115:461 Pregnancy related hyperten- Risk factor, 116:127 Thrombin, 115:123; 116:67, sion, 115:387 Risk factors, 116:365 525 Pregnancy-induced Risk marker, 116:223 Thrombin clotting time, hypertension, 116:377 rt-PA, 116:519 115:9 Premature coronary artery Thrombin formation, 116:33 disease, 116:287 Thrombin generation, 116:483 Saphenous vein grafts, 115:25 Pretest probability, 116:101 Thrombocytopathy, 116:483 Sepsis, 115:536; 116:91 Proanthocyanidin, 115:115 Thrombocytopenia, 115:79 SERMs—Selective Estrogen Procoagulant effect, 116:421 Thromboembolism, 115:3 Receptor Modulators, 116:1 Procoagulant markers, 115:277 Thrombogenesis, 116:293 SF, 115:53 Proexosite |, 115:123 Thrombolysis, 115:341; 116:139, Shark cartilage extract, 115:143 Prognostic factors, 115:59 403, 519 Shear stress, 115:211 Prokaryotic expression, Thrombomodulin, 115:417; Shear-stress, 115:115 116:385 116:181, 249, 471 Sialic acid, 115:293 Promoter polymorphisms, Thrombophilia, 115:461, 519; Single chain Fv fragment, 115:393 116:109, 133, 301 116:385 Prophylaxis, 116:365 Thromboplastin antecedent, Soluble E-selectin, 116:321 Prostacyclin, 115:367 115:441 Specimen collection, 116:249 Protein C, 115:519; 116:15 Thromboplastin, 115:239; Sphingosine 1-phosphate, Protein kinase G inhibitor, 116:421 115:409 115:435 Thrombopoietin, 116:51 Sphingosine kinase, 115:409 Protein S, 115:519 Thrombosis, 115:39, 101, 399; Spirits, 115:31 Prothombin fragment (F1.2), 116:55, 121, 127, 199, 265, Spontaneous thrombolysis, 115:469 403, 431, 525 116:127 Prothrombin complex concen- Thrombospondin-1, 116:533 STA Liatest, 116:165 trate, 115:455 Thromboxane, 115:367 Stability, 116:249 Prothrombin time, 115:9, 239; Thromboxane A>, 115:309 Stable angina, 115:65; 116:25 116:171 Thrombus, 116:431 Staphylococcus aureus, 116:145 Prothrombinase complex, Tirofiban, 116:55 Stasis, 115:527 115:123; 116:533 Tissue factor, 116:75, 233, 471 Statins, 115:469 P-selectin, 115:263; 116:241, Tissue factor (TF), 115:469; Stents, 115:101, 245 377 116:409 Streptokinase, 116:139 Psychological stress, 115:175 Tissue factor pathway inhibitor Streptokinase-induced arterial PT (prothrombin time), (TFPI), 115:469; 116:409 patency, 115:427 115:131 Tissue inhibitor of metallopro- Stroke risk stratification, Pulmonary arterial aneurysms, teinase, 115:205 116:321 115:159 Tissue plasminogen activator, Stroke, 115:393 Pulmonary embolism, 115:381; 115:109, 435 Structure and function of 116:101, 301 Tissue-type plasminogen activa- antithrombin, 115:351 Pulmonary thromboembolism tor, 116:357 Sulphated flavonoids, 115:495 (PTE), 115:271 TLR, 115:536 Superoxide anions, 116:157 TNF-a, 115:393, 417 Survival, 115:59 Total antioxidant capacity, Syndrome X, 116:25 Raloxifene, 116:1 116:157 Systemic inflammatory Randomized controlled clinical Total knee arthroplasty (TKA), response syndrome (SIRS), trial, 115:31 115:271 116:91 Randomized trial, 116:279 tPA, 116:223 Rat, 115:527 tPA-PAI-1 complex, 116:249 Reactive oxygen species, TAFI, 116:265 Transforming growth factor 115:319 TAFI and thrombosis, 115:287 beta-1, 116:233